Case Studies
Iron Fortification and the Kenyan Infant Gut Microbiome: A Randomized Trial
Clinical Overview
This double-blind randomised trial in rural coastal Kenya tested daily iron-containing micronutrient powders (2.5 mg Fe as NaFeEDTA or 12.5 mg Fe as ferrous fumarate) added to maize porridge in 6-month-old, mostly breastfed infants over 4 months. Iron fortification shifted the gut microbiome toward enterobacteria and away from bifidobacteria, increased pathogenic Escherichia coli by about 1.5 log₁₀ copies/g stool, and raised faecal calprotectin from 123 to 229 mg/g, indicating intestinal inflammation. A trend toward more treated diarrhoea occurred in the 12.5 mg group, while iron status and linear growth improved only with 12.5 mg ferrous fumarate.
What was reviewed and who was studied
The paper reports two parallel double-blind RCTs in 115 Kenyan infants (final n=101) aged 5.5–6 months from a malaria-endemic, low-sanitation rural community. Infants received maize porridge fortified with either 2.5 mg Fe as NaFeEDTA, 12.5 mg Fe as ferrous fumarate, or identical iron-free micronutrient powders for 4 months. Primary outcomes were faecal microbiome composition by 16S rRNA pyrosequencing and qPCR; secondary outcomes included faecal calprotectin, short-chain fatty acids, iron status, growth and morbidity, particularly diarrhoea.
Major findings
| Finding | Detail |
|---|---|
| Baseline gut ecology | At 6 months, Actinobacteria (64.3%) dominated, with Bifidobacteriaceae comprising 63% of total 16S rRNA reads; yet high carriage of C. difficile (56.5%), C. perfringens group (89.7%), S. aureus (65.4%), Salmonella (22.4%) and multiple pathogenic E. coli pathotypes was observed. |
| Iron-driven taxonomic shifts | Iron MNPs increased Escherichia/Shigella and Clostridium genera and reduced Bifidobacterium (significant in the 12.5 mg ferrous fumarate arm), shifting the microbiome from a bifidobacteria-dominated to more enterobacteria- and Firmicutes-rich profile. |
| Enterobacteria / bifidobacteria balance | The enterobacteria: bifidobacteria ratio increased significantly with iron by both pyrosequencing and qPCR at 4 months (p=0.004 and p=0.008 respectively), in both low- and high-dose arms, indicating a consistent ecological shift. |
| Pathogenic E. coli expansion | The summed pathogenic E. coli burden was higher with iron at endpoint (6.0±0.5 vs 4.5±0.5 log copies/g faeces, p=0.029), with effects particularly evident in infants who were iron deficient at baseline. |
| Intestinal inflammation | Faecal calprotectin rose with iron (229.2±1.9 vs 123.3±2.1 mg/g, p=0.002), driven by 12.5 mg ferrous fumarate (248.9±2.2 vs 102.5±2.2 mg/g, p=0.008). Associations were observed between calprotectin and enterobacteria and pathogenic E. coli. |
| Clinical outcomes & iron status | In the 12.5 mg ferrous fumarate group, body iron and ferritin improved and sTfR and ZPP decreased (all p≤0.039), with greater linear growth (70.2 vs 68.1 cm, p=0.011) but a trend to more treated diarrhoea (27.3% vs 8.3%, p=0.092). The 2.5 mg NaFeEDTA MNP did not improve iron status. |
Implications for Microbial Metallomics
The study demonstrates that luminal iron dosing in early infancy functionally reconfigures the intestinal metallome, favouring iron-requiring enterobacteria and attenuating the dominance of bifidobacteria in a high-pathogen, phytic-acid–rich dietary context.
| Concept | Implication |
|---|---|
| Ferrous vs ferric iron entry to colon (ferrous fumarate vs ferric NaFeEDTA, with most unabsorbed iron arriving as ferric then reduced in the low-oxygen colon) | Different iron species and doses may differentially fuel microbial iron acquisition systems (siderophore- and FeoB-mediated uptake), potentially tuning pathogen competitive fitness and virulence expression. |
| Enterobacteria–bifidobacteria ratio as an iron-sensitive metric | The enterobacteria:bifidobacteria ratio emerges as a metallomic readout of iron exposure in weaning infants, integrating both iron availability and microbiome resilience, and may serve as a functional biomarker of adverse iron dosing. |
| Pathogenic E. coli expansion in iron-deficient infants | Iron fortification disproportionately increased pathogenic E. coli in infants who were iron deficient at baseline, indicating that host iron status modulates microbiome response to luminal iron and may identify high-risk subgroups. |
| Calprotectin–microbe linkage | Increased faecal calprotectin with iron, correlating with enterobacteria and pathogenic E. coli, links iron-driven microbiome shifts to neutrophil-rich mucosal inflammation, providing a host–microbe metallomic endpoint. |
| Loss of butyrate producers (Roseburia/Eubacterium rectale) | Iron-associated reductions in major butyrate producers suggest that iron perturbation may affect SCFA-generating guilds independently of bulk faecal SCFA levels, highlighting the value of taxon-resolved functional readouts. |
| Context of high phytic acid and inflammation | In a maize- and phytic-acid–based diet with frequent inflammation, low systemic absorption and high colonic iron flux make the microbiome an unintended primary target of iron interventions, redefining safety considerations for fortification strategies. |
Limitations
The sample size was modest (n=101) and restricted to a single rural Kenyan setting, limiting generalisability. High exclusion due to antibiotic use may have selected for relatively healthier infants. Faecal microbiota and SCFA measures may not fully reflect mucosal communities or in situ metabolite gradients. Diarrhoea outcomes, though suggestive, were underpowered and based on treated episodes rather than active surveillance.
Future perspectives
Next steps logically include trials comparing lower iron doses, alternative iron complexes, or co-formulation with microbiota-supportive components (for example, bifidogenic substrates) using the same maize-porridge matrix. Stratified designs by baseline iron status and anaemia could clarify which infants experience net benefit versus harm. Mechanistic work should integrate metagenomics, pathogen virulence gene expression and mucosal biomarkers alongside faecal calprotectin. Longer follow-up could link early iron-induced microbiome shifts to subsequent growth, vaccine responses and recurrent diarrhoea within similar high-pathogen environments.
Key takeaways for Researchers and Clinicians
In 6–10-month-old, breastfed Kenyan infants consuming maize porridge, daily iron fortification with either 2.5 mg ferric NaFeEDTA or 12.5 mg ferrous fumarate altered the gut ecosystem from bifidobacteria-dominant toward enterobacteria- and Clostridium-rich communities. Iron, delivered mainly as unabsorbed luminal Fe³⁺/Fe²⁺, was associated with increased pathogenic E. coli loads, elevated faecal calprotectin, and a trend toward higher diarrhoea, while only the higher ferrous fumarate dose improved iron status and linear growth.
Methodologically, the study highlights 16S pyrosequencing combined with targeted qPCR and calprotectin as a practical microbial metallomics toolkit in paediatric trials. Clinically, the work supports targeting iron-containing MNPs to infants with clear iron deficiency anaemia, particularly in high-infection settings, rather than universal use during weaning. A concise translational hook is that “in weaning infants, the gut microbiome may be the primary organ receiving iron fortification,” and its response should be integral to evaluating iron-based interventions.
Citation
Jaeggi T, Kortman GAM, Moretti D, et al. Iron fortification adversely affects the gut microbiome, increases pathogen abundance and induces intestinal inflammation in Kenyan infants. Gut. 2015;64:731–742